American Diabetes Association Scientific Sessions 2019

Canagliflozin Beneficial for Type 2 Diabetes Patients with Chronic Kidney Disease

Type 2 diabetes (T2D) patients with chronic kidney disease (CKD) may find improved cardiovascular and renal outcomes with canagliflozin,...

Semaglutide Could Minimize CV Events in High-risk Patients with Type 2 Diabetes

A study of more than 3,183 patients found that oral semaglutide may reduce the risk of cardiovascular (CV) events...
Is the Risk of Bladder Cancer Elevated in Patients Taking CVD-Preventing Medications?

Delayed Diabetes Diagnosis Reduces CVD Risk

According to a study presented at the American Diabetes Association’s 79th Scientific Sessions in San Francisco, patients with impaired glucose tolerance (IGT) could decrease their risk of cardiovascular disease
Chronic Kidney Disease Linked to Risk for Aortic Stenosis

Dulaglutide Safe for T2D Patients with Kidney Disease

According to the findings of the AWARD-7 study, which were presented at the American Diabetes Association’s (ADA’s) 79th Scientific Sessions in San Francisco, dulaglutide is a safe medication for type 2 diabetes (T2D) patients with moderate-to-severe chronic kidney disease (CKD).
Renal Transplantation among Patients with ESRD Due to Lupus Nephritis

No Significant Differences in CV Outcomes for Linagliptin and Glimepiride

A multi-center, international trial found that type 2 diabetes (T2D) medications linagliptin and glimepiride have similar safety profiles among patients at high-risk for cardiovascular outcomes.

Curated Journal Abstracts

Advertisement
click me